Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Illumina, Inc.NASDAQ: ILMN
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 11.3% from a year ago
Cash & equivalents stood at $1.04B at the end of Q2 FY2026, up 11.3% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.
Context
- Cash & equivalents amounted to 15.6% of total assets at the end of Q2 FY2026, up 0.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +11.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 1.42B USD
- Year-over-year change
- +25.8%
- 4-year CAGR
- +3.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 1.42B | +25.8% |
| FY2024 | 2024-12-29 | 1.13B | +7.5% |
| FY2023 | 2023-12-31 | 1.05B | -47.9% |
| FY2022 | 2023-01-01 | 2.01B | +63.2% |
| FY2021 | 2022-01-02 | 1.23B | — |
Cash & Equivalents vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's Jun 2026 cash & equivalents of $1.04B is the 2nd highest of the 11 companies compared; the peer median is $134.97M.
- Its year-over-year change of +11.3% is the 5th highest of 11, against a peer median of +6.4%.
- Cash & equivalents amounts to 15.6% of total assets for ILMN, versus a peer median of 31.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.09B | +9.1% | +32.2% | 41.1% | |
| Jun 2026 | $1.04B | +11.3% | -11.0% | 15.6% | |
| Sep 2026 | $1.03B | +77.0% | +38.7% | 54.5% | |
BLLNBillionToOne, Inc. | Jun 2026 | $548.63M | +190.3% | — | 75.2% |
| Sep 2026 | $526.19M | +21.7% | +29.2% | 49.5% | |
| Jun 2026 | $145.54M | -5.9% | -15.4% | 10.8% | |
| Mar 2026 | $124.4M | +35.5% | +38.0% | 18.5% | |
| Mar 2026 | $73.59M | +3.7% | +11.7% | 22.6% | |
| Mar 2026 | $65.39M | -4.6% | -24.2% | 41.7% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $60.32M | -18.6% | -8.6% | 12.5% |
| Mar 2026 | $56.29M | -3.8% | -41.9% | 7.2% | |
| Peer median (excluding ILMN) | $134.97M | +6.4% | +11.7% | 31.8% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.23B | 2.01B | 1.05B | 1.13B | 1.42B |
| Short-term Investments | 107M | 26M | 6M | 93M | 215M |
| Net Receivables | 664M | 688M | 752M | 751M | 854M |
| Inventory | 431M | 568M | 587M | 547M | 564M |
| Other Current Assets | 0 | 268M | 216M | 228M | 238M |
| Total Current Assets | 2.71B | 3.56B | 2.61B | 2.75B | 3.29B |
| Property, Plant & Equipment (Net) | 1.7B | 1.74B | 1.55B | 1.23B | 1.13B |
| Goodwill | 7.11B | 3.24B | 2.55B | 1.11B | 1.11B |
| Intangible Assets | 3.25B | 3.29B | 2.99B | 295M | 210M |
| Long-term Investments | 213M | 211M | 196M | 227M | 338M |
| Tax Assets | 0 | 0 | 0 | 567M | 454M |
| Other Non-current Assets | 232M | 212M | 217M | 121M | 111M |
| Total Non-current Assets | 12.5B | 8.69B | 7.5B | 3.56B | 3.36B |
| Total Assets | 15.22B | 12.25B | 10.11B | 6.3B | 6.64B |
| Account Payables | 332M | 293M | 245M | 221M | 240M |
| Short-term Debt | 0 | 1.25B | 0 | 578M | 499M |
| Tax Payables | 98M | 97M | 79M | 101M | 0 |
| Deferred Revenue | 234M | 245M | 252M | 260M | 270M |
| Other Current Liabilities | 241M | 188M | 223M | 70M | 249M |
| Total Current Liabilities | 1.09B | 2.77B | 1.57B | 1.55B | 1.59B |
| Long-term Debt | 1.7B | 1.49B | 1.49B | 1.49B | 1.49B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 67M | 0 |
| Other Non-current Liabilities | 915M | 649M | 620M | 272M | 360M |
| Total Non-current Liabilities | 3.38B | 2.88B | 2.8B | 2.38B | 2.34B |
| Total Liabilities | 4.48B | 5.65B | 4.37B | 3.93B | 3.92B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 5.49B | 1.14B | (19M) | (1.24B) | (392M) |
| Accumulated OCI | 17M | 3M | (1M) | 22M | (10M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 10.74B | 6.6B | 5.75B | 2.37B | 2.72B |
| Total Debt | 2.54B | 3.56B | 2.26B | 2.62B | 2.55B |
| Net Debt | 1.31B | 1.54B | 1.21B | 1.5B | 1.14B |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.